Background-Most investigations of novel biomarkers for prediction of cardiovascular disease pertain to coronary artery disease. Few large-scale prospective studies have critically assessed plasma-based factors as predictors of peripheral arterial disease (PAD), and comparative data between individual biomarkers and lipid levels are sparse, especially among women. Methods and Results-We evaluated the relationship between baseline levels of several novel biomarkers and confirmed incident symptomatic PAD (nϭ100) in a prospective cohort study (median follow-up, 12.3 years) involving 27 935 US female health professionals Ն45 years of age without diagnosed vascular disease at baseline. Biomarkers assessed were high-sensitivity C-reactive protein, fibrinogen, soluble intercellular adhesion molecule-1 (sICAM-1), homocysteine, lipoprotein(a), hemoglobin A 1c , creatinine, and conventional lipid levels. In univariate analyses, levels of high-sensitivity C-reactive protein, fibrinogen, sICAM-1, homocysteine, lipoprotein(a), creatinine clearance, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and the ratio of total cholesterol to HDL-C (TC:HDL-C) were significantly related to PAD (all PϽ0.05). However, after multivariable adjustment, risk associations were significant only for highsensitivity C-reactive protein (adjusted hazard ratio [HR] extreme tertiles, 2.1; 95% confidence interval, 1.2 to 3.7), sICAM-1 (adjusted HR, 4.0; 95% confidence interval, 1.9 to 8.6), HDL-C (adjusted HR, 0.4; 95% confidence interval, 0.3 to 0.8), and TC:HDL-C (adjusted HR, 2.2; 95% confidence interval, 1.2 to 3.9). In a model simultaneously controlling for traditional risk factors plus these significant biomarkers, sICAM-1 remained independently predictive of PAD (adjusted HR in each tertile, 1.0 [reference], 2.3, and 3.5).
P rospective data pertaining to both traditional and novel risk factors for lower-extremity peripheral arterial disease (PAD) have been less available than for coronary or cerebrovascular disease, particularly in women. Nonetheless, most traditional cardiovascular risk factors, including smoking, diabetes, dyslipidemia, and hypertension, are generally accepted clinical predictors of PAD. Existing data suggest that the relative impact of these exposures in the peripheral vasculature differs from the coronary circulation, 1 thereby invoking potential site-specific atherogenic mechanisms. Furthermore, although biological processes such as subclinical inflammation, thrombosis, and endothelial dysfunction are linked to the incidence of myocardial infarction and stroke, relatively few prospective studies have evaluated the role of these emerging risk factors in the pathogenesis of PAD. We previously reported comparative data for a broad range of atherothrombotic biomarkers for clinical PAD in a large population of healthy men followed in the Physicians' Health Study (PHS). 2, 3 However, similar prospective data pertaining to unique risk factor associations in women are sparse.
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To address these issues, we evaluated several novel biomarkers and conventional lipids as predictors of symptomatic PAD in a large-scale study of initially healthy middleaged and older American women. Biomarkers were chosen on the basis of prior reports of risk assessment for coronary and cerebrovascular disease and available data for PAD and included high-sensitivity C-reactive protein (hsCRP), fibrinogen, soluble intercellular adhesion molecule-1 (sICAM-1), homocysteine, lipoprotein(a) [Lp(a)], hemoglobin A 1c (HbA 1c ), creatinine, and standard lipid parameters.
Methods

Study Population
The Women's Health Study (WHS) 4 is a recently completed randomized trial of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer. Between November 1992 and July 1995, a total of 39 876 US female health professionals Ն45 years of age without prior cancer or cardiovascular disease (including myocardial infarction, stroke, coronary, and peripheral arterial revascularization) were enrolled and randomized into the study. Subjects alive and willing to be contacted were invited to participate in the ongoing observational component of the WHS. Participants provided baseline information on behavioral, lifestyle, and demographic factors and are followed prospectively by annual questionnaire. Morbidity and mortality data are available on 99% and 100% of participants, respectively.
Before randomization, 28 345 participants provided blood specimens, which were stored in liquid nitrogen (Ϫ150°C to Ϫ180°C) until analysis. Of the samples received, 27 939 were usable for determination of the analytes of interest. Subjects with confirmed prerandomization PAD (nϭ4) were excluded from analysis. The final study population (nϭ27 935) was followed up for a median of 12.3 years. Fewer than 3% of data were missing for major vascular risk factors, including age, hypertension, diabetes, smoking, body mass index (BMI), and menopausal hormone therapy (HT).
Outcome Ascertainment
WHS participants are surveyed annually for several health outcomes, including PAD events, defined as intermittent claudication and/or peripheral arterial surgery. As of January 5, 2007, 407 such events were reported. Case confirmation occurred by telephone interview during which the presence of vascular claudication was established with the Edinburgh Claudication Questionnaire. This instrument is a modified version of the World Health Organization/Rose Claudication Questionnaire, which has previously been validated in a community outpatient setting with 92% sensitivity and 99% specificity for physician-diagnosed intermittent claudication. 5 In addition, medical records were obtained to assess the concordance of reported symptoms with diagnostic testing when available. Reports of peripheral arterial surgery were confirmed after review of operative notes or procedural reports in the case of peripheral angioplasty or stenting. Of 407 self-reported PAD events, 100 were confirmed with these methods. Among disconfirmed events, venous disease, lowerextremity arthritis, lumbar disk disease, and peripheral neuropathy were the main causes of nonischemic leg pain. There were 73 unrefuted events in women who were unreachable for telephone interview, deceased, or unwilling to participate. These were included in sensitivity analyses only.
Laboratory Analysis
Analytes were measured in a core laboratory certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization Program. Plasma hsCRP was measured with a validated high-sensitivity immunoturbidimetric method (Denka Seiken, Niigata, Japan). Fibrinogen was determined with an immunoturbidimetric assay (Kamiya Biomedical Co, Seattle, Wash). Homocysteine was measured with an enzymatic assay (Catch Inc, Seattle, Wash). Lp(a) was determined by a latex-enhanced turbidimetric method independently of apolipoprotein(a) isoform size and kringle IV type 2 repeats with reagents and calibrators from Denka Seiken. HbA 1c was estimated with the Tina-Quant turbidimetric inhibition immunoassay (Roche Diagnos-tics, Indianapolis, Ind) on packed red blood cells. Plasma creatinine was quantified by a rate-blanked method that is based on the Jaffé reaction (Roche Diagnostics). Creatinine clearance was estimated by use of the Cockcroft-Gault formula for women 6 and standardized to body surface area. Total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) were measured enzymatically, and low-density lipoprotein cholesterol (LDL-C) was determined by a homogenous direct method (Genzyme, Cambridge, Mass). Non-HDL-C was calculated by subtracting HDL-C from TC. The abovementioned analytes were measured on the Hitachi 917 analyzer from Roche Diagnostics. The interassay coefficients of variation using 2 levels of control materials ranged from 1.07% to 5.20%. sICAM-1 was measured by quantitative sandwich ELISA (R&D Systems, Minneapolis, Minn) with a reproducibility of 8.89% and 6.39% at concentrations of 171.8 and 289.1 ng/mL, respectively.
Statistical Analysis
Continuous data are summarized as either meanϮSD or median and interquartile range based on normality of distributions. Categorical data are expressed as percentages. Between-group differences were assessed by the unpaired 2-tailed Student t test and the Wilcoxon rank-sum test as appropriate. Categorical data were analyzed with the 2 test. Women were classified on the basis of thirds (tertiles) of baseline biomarker values. Cox proportional-hazards models were then constructed, estimating the hazard ratio (HR) and 95% confidence interval (CI) according to biomarker tertiles with the lowest tertile as referent. Tests of linear trend across tertiles were computed using median values within each tertile. With a linear effect over tertiles assumed, these analyses are estimated to have Ϸ83% power to detect a linear trend and an HR of 2.1 in the highest versus lowest tertile.
Multivariable estimates were derived from models adjusting for age, smoking (never, past, current), baseline history of diabetes (no/yes), baseline history of hypertension (no/yes self-report Ն140/ 90 mm Hg), BMI (linear continuous), and menopausal HT. Linearity assumptions for continuous variables were assessed by quadratic and natural log transformations and through the use of regression splines. Age was modeled using a natural log transformation, and BMI was entered as a linear term. Model fit was compared by the likelihood ratio 2 statistic, with a higher value indicating superior fit. To assess for effects independent of other biomarkers, significant markers identified during the initial analysis were entered together in a single model.
Secondary analyses adjusted for race/ethnicity, parental history of myocardial infarction, exercise frequency, and randomized treatment assignment. Sensitivity analyses included cases of unrefuted PAD events. Kaplan-Meier survival curves were plotted, and differences in event-free survival according to biomarker tertile were assessed with the log-rank test for multiple-group comparison. To evaluate joint effects of biomarker combinations, women were divided into 4 groups based on median cut points of each predictive biomarker and multivariable HRs computed from Cox regression models. All 95% CIs are 2-tailed and calculated at the 0.05 level. Analyses in data tables and figures were conducted with SAS statistical software version 9.1 (SAS Institute, Cary, NC).
The institutional review board approved the study, and all subjects provided informed consent. The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Overall, the incidence of symptomatic PAD was low (0.03 annualized percentage). As expected, women developing peripheral arterial events were older and were more likely to smoke and have baseline diagnosed diabetes, hypertension, and dyslipidemia (Table 1 ). As shown in Table 2 , plasma levels of hsCRP, fibrinogen, sICAM-1, homocysteine, Lp(a), non-HDL-C, and ratio of TC to HDL-C (TC:HDL-C) were all higher in subjects with incident PAD. Levels of HDL-C and estimated creatinine clearance were lower, and no statistically significant difference was noted in HbA 1c , creatinine, TC, or LDL-C. Table 3 shows results of age-adjusted and multivariableadjusted analyses after women were classified according to baseline biomarker tertiles. In both age-adjusted and multivariable-adjusted models, sICAM-1 was the strongest predictor, with a 4-fold increase in risk in the highest versus lowest tertile (adjusted HR, 4.0; 95% CI, 1.9 to 8.6; P for trend Ͻ0.001). There was a 2-fold increase in risk associated with elevated hsCRP (adjusted HR, 2.1; 95% CI, 1.2 to 3.7; P for trendϭ0.03) and TC:HDL-C (adjusted HR, 2.2; 95% CI, 1.2 to 3.9; P for trendϭ0.02]. The latter finding appeared to be driven largely by elevated HDL-C levels because this factor but not TC was significantly associated with risk; women in the highest tertile of HDL-C had a 60% lower risk (adjusted HR extreme tertiles, 0.4; 95% CI, 0.3 to 0.8; P for trendϭ0.004). A modest and borderline nonsignificant result was noted for Lp(a) (adjusted HR extreme tertiles, 1.6; 95% CI, 1.0 to 2.6; Pϭ0.07; P for trendϭ0.050). In contrast, in multivariable analyses, no significant effects were observed for homocysteine, HbA 1c , creatinine, creatinine clearance, TC, LDL-C, and non-HDL-C. Comparison of the model likelihood ratio 2 statistic, a global measure of model fit with larger values indicating superior fit, showed that the model with sICAM-1 had the highest value (147.5; dfϭ9), followed by HDL-C (137.9; dfϭ9), TC:HDL-C (136.8; dfϭ9), hsCRP (135.1; dfϭ9), and Lp(a) (134.1; dfϭ9).
In a model that included hsCRP, sICAM-1, and HDL-C, as well as traditional risk factors, sICAM-1 remained significantly associated with incident PAD with a slightly attenuated effect (adjusted HR for increasing tertiles, 1.0 [reference], 2.3, and 3.5; P for trend Ͻ0.001). However, hsCRP was no longer significant (P for trendϭ0.3). HDL-C also remained predictive (adjusted HR for increasing tertiles, 1.0, 0.7, and 0.5; P for trendϭ0.03). Additional adjustment for race/ethnicity, physical activity, parental history of premature coronary disease, and randomized treatment assignment did not alter these risk associations; in this expanded model, the HR for highest versus lowest tertile of sICAM-1 was 4.0 (95% CI, 1.9 to 8.7; P for trend Ͻ0.001). Our main findings persisted in analyses that also included unrefuted PAD events (data not shown). PAD cumulative incidence curves are shown in Figure 1 . Although modest overlap is evident when women are classified by either hsCRP or HDL-C (log-rank Pϭ0.007 and Ͻ0.001, respectively), there is better separation of curves according to TC:HDL-C (PϽ0.001) and sICAM-1 (PϽ0.001), with clear delineation of risk in the highest sICAM-1 tertile.
To evaluate the potential joint role of lipid and inflammation parameters in PAD risk, HRs were estimated after classification based on median values of HDL-C, TC:HDL-C, and each inflammatory marker ( Figure 2 ). As shown, at lipid levels either below or above the population median, the presence of elevated inflammatory markers was associated with a higher risk for PAD. Overall, risk estimates were consistently higher for women with high levels of sICAM-1.
Discussion
In this prospective evaluation of biomarkers for PAD development in women, we found the proinflammatory cellular adhesion molecule sICAM-1 to be the strongest predictor of confirmed clinical events. hsCRP, HDL-C, and TC:HDL-C also were significant, although of lower magnitude, with borderline nonsignificant results for Lp(a). In this otherwise healthy population, after adjustment for concomitant cardiovascular risk factors and HT use, we did not find significant associations for fibrinogen, homocysteine, HbA 1c , creatinine, estimated creatinine clearance, TC, LDL-C, or non-HDL-C. To the best of our knowledge, this study is the first prospective analysis of PAD in women to provide comparative data for the most commonly evaluated novel biomarkers, including indicators of dysglycemia and renal dysfunction, against each other and conventional lipid levels.
Findings from most [7] [8] [9] [10] [11] [12] but not all 13, 14 previously published prospective reports suggest that the impact of traditional risk factors on PAD development may differ from that for incident coronary and cerebrovascular disease. This observation may relate to the acuity of events under consideration, thereby implicating factors differentiating plaque rupture from systemic atherosclerosis progression. In most largescale epidemiological studies, PAD is determined as the first occurrence of intermittent claudication, revascularization, or decline in ankle-brachial index, which in most instances is subacute in nature. In contrast, studies of incident coronary and cerebrovascular disease commonly evaluate "hard" end points such as myocardial infarction, stroke, or cardiovascular death that are generally characterized by sudden, obliterative vascular occlusion. Although atheromatous disease is a common underlying feature, factors predisposing to abrupt plaque rupture differ from those causing more gradual luminal obstruction. In this regard, we believe our findings of a prominent effect of sICAM-1 may offer additional mechanistic insight.
Cellular adhesion molecules are principal mediators of leukocyte-endothelial cell interactions. Leukocyte recruitment is an initial event during atherogenesis during which ICAM-1 facilitates high-affinity adhesion and transmigration of inflammatory cells into the subendothelial space. This process, when unabated, is implicated in endothelial dysfunction, tissue injury, and ensuing atherosclerosis. Although ICAM-1 is constitutively expressed on many cell types, de novo synthesis undergoes dynamic transcription-dependent regulation in endothelial cells with marked heterogeneity between different vascular beds. Importantly, ICAM-1 is preferentially expressed in endothelium overlying human atheroma, 15 and the circulating level of sICAM-1 shed from the endothelial surface is a proposed index of endothelial activation. 16 Although CRP elevation before the onset of vascular disease may be expected on the basis of known inflammatory triggers, biomechanical activation may be a unique proinflammatory stimulus for ICAM-1 because transcriptional upregulation by both laminar 17 and oscillatory 18 shear stress has been previously described. Moreover, biomechanical forces are particularly relevant at arterial bifurcations where local geometry is a major determinant of wall stress. Interestingly, these branch points in the peripheral vasculature are also atheroma prone. Furthermore, during progressive luminal stenosis, monocyte adhesion to shear stress-activated endothelium via ICAM-1-dependent interactions precedes neovascularization and collateral vessel formation. 19 The present results and our previous analysis in healthy men 3 concur with these experimental observations. Our findings provide confirmation that sICAM-1 is a potent predictor of clinical PAD and suggest that this effect appears stronger than for coronary or cerebrovascular events. Indeed, a meta-analysis of 5 prospective studies of sICAM-1 and incident coronary heart disease (myocardial infarction or death) suggested a modest effect, if any, after multivariable adjustment. 20 In the WHS, sICAM-1 was not predictive of the combined end point of incident myocardial infarction, coronary revascularization, or stroke. 21 However, when events were analyzed separately, levels were predictive of coronary atherosclerosis progression (HR extreme quintiles, 1.6; P for trendϭ0.008) but not myocardial infarction or stroke. 22 In contrast to our findings for sICAM-1, hsCRP, HDL-C, TC:HDL-C, and to a lesser degree Lp(a), we found no evidence of association for other commonly assessed novel biomarkers. Prior data in this regard have been limited and heavily reliant on cross-sectional or retrospective reports of individuals with prevalent disease. However, a recent prospective analysis of symptomatic PAD (intermittent claudication, critical limb ischemia, or surgical intervention) in the Edinburgh Artery Study 23 found significant associations for CRP, Lp(a), and fibrinogen but not sICAM-1 among a broad range of inflammatory, hemostatic, and rheological factors assessed. Importantly, subjects with baseline coronary disease (Ϸ14%) were included in the analysis, and because this characteristic alone was the strongest predictor of subsequent PAD, this inclusion may have influenced the observed relationships. A related analysis of PAD progression in the Edinburgh population demonstrated that sICAM-1 levels were strongly associated with declining ankle-brachial index. 24 Data for fibrinogen are conflicting, with no significant association in a French population-based study of men and women. 25 However, in our prior report from the PHS, 2 we found a 2-fold increase in risk among men in the highest versus lowest fibrinogen quartile (adjusted relative risk [RR] for extreme quartiles, 2.2; P for trendϭ0.02). No association was found for homocysteine. To the best of our knowledge, prospective data are otherwise unavailable.
Our findings pertaining to Lp(a) require further discussion. Prior reports have been mixed, with most studies demonstrating a modest effect of a magnitude similar to that in the present analysis. In the Framingham Heart Study, the presence of sinking pre-beta lipoprotein, a putative surrogate marker for Lp(a), was an independent predictor (adjusted RR, 1.94; 95% CI, 1.1 to 3.5) of intermittent claudication in women. 26 Similarly, in the Edinburgh Artery Study, 27 after exclusion of subjects with baseline cardiovascular disease, the adjusted RR for intermittent claudication was 1.20 (95% CI, 0.99 to 1.45) overall with a slightly higher RR for women (adjusted RR, 1.40; 95% CI, 1.03 to 1.92). We found no significant association among men in the PHS. 2 Although the lack of statistical significance in the present analysis may relate to the low event rate, the magnitude of effect is consistent with prior findings in women and modest compared with our results for sICAM-1 and hsCRP. Additionally, a strength of our Lp(a) analysis is the use of an assay unaffected by apolipoprotein(a) isoform size and kringle type 2 repeats.
Although diabetes is a major risk factor for PAD and among diabetic patients both glycemic control 28 and diabetes duration 29 are strongly associated with PAD risk, prospective data with regard to HbA 1c as a marker of dysglycemia in the general population are sparse. In this cohort of initially healthy women with a low baseline prevalence of diabetes, we found no association between HbA 1c and future PAD. We also found no association with markers of renal dysfunction as has been previously documented. 30, 31 It is important to note, however, that few women met clinical criteria for renal insufficiency at baseline (creatinine Ն1.4 mg/dL, nϭ91 [0.3%]; creatinine clearance Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 , nϭ936 [3.5%] ). In addition, we did not use other potentially more sensitive measures of incipient diabetes or kidney disease such as fasting or postload glucose and cystatin C, which have previously been shown to discriminate PAD risk. 32, 33 Of conventional lipids, HDL-C and TC:HDL-C were the only significant predictors, suggesting that the lipid profile encountered in women at risk for PAD more typically resembles the dyslipidemia of insulin resistance. In contrast to prior data in men 2, 9, 10 and older individuals, 14 we did not discern an independent effect of TC or LDL-C. In the Framingham 11 and Edinburgh 23 studies, TC (20% increased odds per 40 mg/dL) and the TC:HDL-C ratio (41% increase per 1.9 U) were independent predictors in populations of middle-aged and older men and women. Estimates were not provided separately for women. Prospective data in women otherwise derive from the Heart and Estrogen/Progestin Replacement Study, 34 in which HDL-C but not LDL-C was predictive among women allocated to placebo. In sum, our results allude to gender-related differences in disease susceptibility and suggest that, as for cardiovascular disease, 35 the atheroprotective effect of HDL-C or insulin sensitivity in women may be more important than other lipid abnormalities.
Potential limitations of our study merit consideration. First, WHS participants do not undergo a health examination. Therefore, the use of symptomatic PAD as our primary a priori end point by definition excludes subclinical disease, which may have otherwise been detected by physical examination through abnormal pulse examination or ankle-brachial index. However, we believe our data to be not only relevant from a mechanistic perspective as discussed above but also of clinical importance for the following reasons. First, claudication and limb ischemia requiring revascularization are the principal clinical manifestations of PAD. Second, selfreported events were confirmed by a validated claudication questionnaire and medical record review. In addition, women enrolled in the WHS are female health professionals and are therefore less likely to encounter barriers to medical care, which may otherwise have led to underdiagnosis. Furthermore, although potential misclassification resulting from atypical or occult disease may have occurred, this, if anything, would have biased our results toward the null by inclusion of potentially misclassified cases in the event-free group. Thus, we believe our use of self-reported symptomatic PAD confirmed by the Edinburgh Claudication Questionnaire and medical record review not only is valid but also represents an important clinical end point.
Another potential limitation is the low event rate in this cohort of healthy women. However, we did achieve 80% power for detecting a linear trend across biomarker tertiles, and although low, our event rate is similar to the Women's Health Initiative 36, 37 in which the annualized percentage ranged from 0.03 to 0.08. Furthermore, our rigorous approach to case validation allowed elimination of spurious reports of nonischemic leg pain, which would likely have altered the observable risk associations. It also should be noted that treatment allocation to low-dose aspirin and/or vitamin E is unlikely to have altered our findings because the cardiovascular risk reduction with either agent in the WHS is small. 4, 22, 38 Furthermore, baseline blood specimens were obtained during the run-in phase before randomization; thus, baseline biomarker levels are unaffected by treatment assignment. Lastly, gender-specific associations are possible and furthermore are supported by our data; thus, caution must be used when our findings are applied to men.
Although there is now clear appreciation of factors such as subclinical inflammation in the development of myocardial infarction and stroke, 39 relatively few prospective data have been presented to evaluate novel risk factors for PAD, especially in women. Although we found that hsCRP and HDL-C are predictive, these data suggest an even greater role for sICAM-1, thus providing human extension of basic work implicating the early process of leukocyte adherence and transmigration as a critical initiating event in atherogenesis. However, the clinical utility of this marker for both risk assessment and potentially therapeutic applications requires corroboration of these results in other large cohorts of healthy individuals and the development of inexpensive, standardized commercial assays. Given the strength of these data and related prior reports on atherosclerosis progression, we believe that assessment of endothelial activation as measured by sICAM-1 levels warrants further investigations in these areas.
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CLINICAL PERSPECTIVE
Lower-extremity peripheral arterial disease (PAD) is an underrecognized manifestation of atherosclerosis warranting greater attention in both clinical research and clinical practice. Far less information has been available about risk factors for PAD than for coronary or cerebrovascular disease, especially among women. Although established cardiovascular risk factors such as smoking, diabetes, hypertension, and dyslipidemia also are clinical predictors of PAD, few prospective studies have evaluated the role of novel or emerging risk factors such as subclinical inflammation, thrombosis, and endothelial dysfunction. This study is the first prospective analysis of PAD in women to provide comparative data for a broad range of more commonly evaluated novel biomarkers against each other, markers of dysglycemia, renal dysfunction, and conventional lipid levels. Biomarkers assessed included high-sensitivity C-reactive protein, fibrinogen, soluble intercellular adhesion molecule-1, homocysteine, lipoprotein(a), hemoglobin A 1c , creatinine, creatinine clearance, and standard lipid parameters. In this large population of initially healthy women Ն45 years of age without prior vascular disease, only 4 factors, soluble intercellular adhesion molecule-1, high-sensitivity C-reactive protein, high-density lipoprotein, and ratio of total cholesterol to high-density lipoprotein cholesterol, were associated with the incidence of symptomatic PAD. The strongest association was noted for soluble intercellular adhesion molecule-1 (adjusted hazard ratio extreme tertiles, 4.0; 95% confidence interval, 1.9 to 8.6; P for trend Ͻ0.001). Increased levels of this proinflammatory cellular adhesion molecule reflect endothelial activation and leukocyte recruitment. Interestingly, prior data from both this cohort and other populations have shown only modest associations of soluble intercellular adhesion molecule-1 with coronary or cerebrovascular disease. The current results thus support the concept that factors predisposing to plaque rupture as manifested by acute coronary events differ from those causing more gradual luminal obstruction as in the pathogenesis of PAD.
